Bicara Therapeutics Inc. BCAX
We take great care to ensure that the data presented and summarized in this overview for Bicara Therapeutics Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in BCAX
Top Purchases
Top Sells
About BCAX
Insider Transactions at BCAX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2025
|
David Raben Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,500
-6.97%
|
$99,000
$18.84 P/Share
|
|
Nov 25
2025
|
David Raben Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+6.35%
|
$16,500
$3.79 P/Share
|
|
Nov 24
2025
|
David Raben Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
5,500
-13.42%
|
$99,000
$18.45 P/Share
|
|
Nov 24
2025
|
David Raben Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,500
+11.83%
|
$16,500
$3.79 P/Share
|
|
Nov 24
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
41,163
-11.73%
|
$740,934
$18.86 P/Share
|
|
Nov 24
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
41,163
+10.49%
|
$123,489
$3.79 P/Share
|
|
Nov 24
2025
|
Ivan Hyep Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,795
-10.91%
|
$320,310
$18.55 P/Share
|
|
Nov 24
2025
|
Ivan Hyep Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
17,795
+9.83%
|
$53,385
$3.79 P/Share
|
|
Nov 21
2025
|
Ryan Cohlhepp President and COO |
SELL
Open market or private sale
|
Direct |
12,500
-3.08%
|
$225,000
$18.05 P/Share
|
|
Nov 21
2025
|
Ryan Cohlhepp President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.74%
|
$24,000
$3.79 P/Share
|
|
Nov 21
2025
|
Ivan Hyep Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
605
-0.41%
|
$10,890
$18.15 P/Share
|
|
Nov 21
2025
|
Ivan Hyep Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
605
+0.41%
|
$1,815
$3.79 P/Share
|
|
Oct 16
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
24,103
-7.22%
|
$433,854
$18.83 P/Share
|
|
Oct 16
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,103
+6.73%
|
$72,309
$3.79 P/Share
|
|
Oct 15
2025
|
Ryan Cohlhepp President and COO |
SELL
Open market or private sale
|
Direct |
12,500
-3.01%
|
$225,000
$18.16 P/Share
|
|
Oct 15
2025
|
Ryan Cohlhepp President and COO |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+3.66%
|
$24,000
$3.79 P/Share
|
|
Oct 15
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,289
-4.11%
|
$239,202
$18.84 P/Share
|
|
Oct 15
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,289
+3.95%
|
$39,867
$3.79 P/Share
|
|
Oct 13
2025
|
Claire Mazumdar Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
11,445
-3.56%
|
$206,010
$18.92 P/Share
|
|
Oct 13
2025
|
Claire Mazumdar Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,445
+3.44%
|
$34,335
$3.79 P/Share
|
Last 12 Months Summary
Buy / Acquisition
371K
Shares
From
5
Insiders
| Exercise of conversion of derivative security | 371K shares |
|---|
Sell / Disposition
398K
Shares
From
5
Insiders
| Open market or private sale | 398K shares |
|---|